{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:06:13Z","timestamp":1785470773701,"version":"3.56.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cholinergic drugs are the most commonly used drugs for the treatment of Alzheimer\u2019s disease (AD). Therefore, a better understanding of the cholinergic system and its relation to both AD-related biomarkers and cognitive functions is of high importance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the relationships of cerebrospinal fluid (CSF) cholinergic enzymes with markers of amyloidosis, neurodegeneration, neurofibrillary tangles, inflammation and performance on verbal episodic memory in a memory clinic cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cross-sectional study, 46 cholinergic drug-free subjects (median age = 71, 54% female, median MMSE = 28) were recruited from an Icelandic memory clinic cohort targeting early stages of cognitive impairment. Enzyme activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) was measured in CSF as well as levels of amyloid-\u03b2<jats:sub>1\u201342<\/jats:sub> (A\u03b2<jats:sub>42<\/jats:sub>), phosphorylated tau (P-tau), total-tau (T-tau), neurofilament light (NFL), YKL-40, S100 calcium-binding protein B (S100B), and glial fibrillary acidic protein (GFAP). Verbal episodic memory was assessed with the Rey Auditory Verbal Learning (RAVLT) and Story tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant relationships were found between CSF A\u03b2<jats:sub>42<\/jats:sub> levels and AChE or BuChE activity (<jats:italic>p<\/jats:italic> &amp;gt; 0.05). In contrast, T-tau (<jats:italic>r<\/jats:italic> = 0.46, <jats:italic>p<\/jats:italic> = 0.001) and P-tau (<jats:italic>r<\/jats:italic> = 0.45, <jats:italic>p<\/jats:italic> = 0.002) levels correlated significantly with AChE activity. Although neurodegeneration markers T-tau and NFL did correlate with each other (<jats:italic>r<\/jats:italic> = 0.59, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), NFL did not correlate with AChE (<jats:italic>r<\/jats:italic> = 0.25, <jats:italic>p<\/jats:italic> = 0.09) or BuChE (<jats:italic>r<\/jats:italic> = 0.27, <jats:italic>p<\/jats:italic> = 0.06). Inflammation markers S100B and YKL-40 both correlated significantly with AChE (S100B: <jats:italic>r<\/jats:italic> = 0.43, <jats:italic>p<\/jats:italic> = 0.003; YKL-40: <jats:italic>r<\/jats:italic> = 0.32, <jats:italic>p<\/jats:italic> = 0.03) and BuChE (S100B: <jats:italic>r<\/jats:italic> = 0.47, <jats:italic>p<\/jats:italic> &amp;lt; 0.001; YKL-40: <jats:italic>r<\/jats:italic> = 0.38, <jats:italic>p<\/jats:italic> = 0.009) activity. A weak correlation was detected between AChE activity and the composite score reflecting verbal episodic memory (<jats:italic>r<\/jats:italic> = \u22120.34, <jats:italic>p<\/jats:italic> = 0.02). LASSO regression analyses with a stability approach were performed for the selection of a set of measures best predicting cholinergic activity and verbal episodic memory score. S100B was the predictor with the highest model selection frequency for both AChE (68%) and BuChE (73%) activity. Age (91%) was the most reliable predictor for verbal episodic memory, with selection frequency of both cholinergic enzymes below 10%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results indicate a relationship between higher activity of the ACh-degrading cholinergic enzymes with increased neurodegeneration, neurofibrillary tangles and inflammation in the stages of pre- and early symptomatic dementia, independent of CSF A\u03b2<jats:sub>42<\/jats:sub> levels.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2022.876019","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T07:46:06Z","timestamp":1653551166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects"],"prefix":"10.3389","volume":"14","author":[{"given":"Unnur D.","family":"Teitsdottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Darreh-Shori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Snaedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petur H.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-0404.1992.tb04458.x","article-title":"Putative mechanisms of action of tacrine in Alzheimer\u2019s disease","volume":"139","author":"Adem","year":"1992","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0122048","DOI":"10.1371\/journal.pone.0122048","article-title":"Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis","volume":"10","author":"Aeinehband","year":"2015","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.neuron.2016.09.006","article-title":"Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline","volume":"91","author":"Ballinger","year":"2016","journal-title":"Neuron"},{"key":"B4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s40520-019-01359-4","article-title":"Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders","volume":"33","author":"Benfante","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","article-title":"Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation","volume":"22","author":"Bonneh-Barkay","year":"2012","journal-title":"Brain Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00401-013-1170-1","article-title":"Reply: the early pathological process in sporadic Alzheimer\u2019s disease","volume":"126","author":"Braak","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.nbd.2006.07.013","article-title":"Differential CSF butyrylcholinesterase levels in Alzheimer\u2019s disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism","volume":"24","author":"Darreh-Shori","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2320.e2315","DOI":"10.1016\/j.neurobiolaging.2010.04.028","article-title":"Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer\u2019s disease in the brain in vivo","volume":"32","author":"Darreh-Shori","year":"","journal-title":"Neurobiol. Aging"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.neurobiolaging.2009.07.015","article-title":"The apolipoprotein E \u03b54 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase","volume":"32","author":"Darreh-Shori","year":"","journal-title":"Neurobiol. Aging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neurobiolaging.2006.09.020","article-title":"Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine","volume":"29","author":"Darreh-Shori","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/JAD-2011-111088","article-title":"Apolipoprotein \u03b54 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer\u2019s disease","volume":"28","author":"Darreh-Shori","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156720510790274455","article-title":"Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer\u2019s disease: a review of recent clinical studies","volume":"7","author":"Darreh-Shori","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.neurobiolaging.2013.04.027","article-title":"Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer\u2019s disease","volume":"34","author":"Darreh-Shori","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.bbamcr.2008.11.009","article-title":"S100B\u2019s double life: intracellular regulator and extracellular signal","volume":"1793","author":"Donato","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neulet.2017.01.036","article-title":"Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer\u2019s disease patients","volume":"641","author":"Gabriel","year":"2017","journal-title":"Neurosci. Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e8701","DOI":"10.1016\/j.onehlt.2021.100325","article-title":"Altered levels of acetylcholinesterase in Alzheimer plasma","volume":"5","author":"Garc\u00eda-Ayll\u00f3n","year":"2010","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cbi.2008.04.047","article-title":"Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer\u2019s cerebrospinal fluid","volume":"175","author":"Garc\u00eda-Ayll\u00f3n","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"B19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00002093-199501002-00005","article-title":"Cholinesterases and the pathology of Alzheimer disease","volume":"9","author":"Geula","year":"1995","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1023\/a:1022869222652","article-title":"Cholinesterases: new roles in brain function and in Alzheimer\u2019s disease","volume":"28","author":"Giacobini","year":"2003","journal-title":"Neurochem. Res."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac096","article-title":"Reimagining cholinergic therapy for Alzheimer\u2019s disease","author":"Giacobini","year":"2022","journal-title":"Brain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12859-015-0575-3","article-title":"Controlling false discoveries in high-dimensional situations: boosting with stability selection","volume":"16","author":"Hofner","year":"2015","journal-title":"BMC Bioinform."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1074\/jbc.272.4.2038","article-title":"Nontoxic amyloid beta peptide 1\u201342 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer\u2019s disease","volume":"272","author":"Hoshi","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1038\/s41598-019-41578-3","article-title":"Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer\u2019s disease","volume":"9","author":"Jasiecki","year":"2019","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3390\/biom9100592","article-title":"Butyrylcholinesterase protein ends in the pathogenesis of Alzheimer\u2019s disease\u2014could BCHE genotyping be helpful in Alzheimer\u2019s therapy?","volume":"9","author":"Jasiecki","year":"2019","journal-title":"Biomolecules"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e81989","DOI":"10.1371\/journal.pone.0081989","article-title":"Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer\u2019s disease","volume":"8","author":"Johansson","year":"2013","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1017\/s003329170002691x","article-title":"A short form of the informant questionnaire on cognitive decline in the elderly (IQCODE): development and cross-validation","volume":"24","author":"Jorm","year":"1994","journal-title":"Psychol. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1046\/j.1471-4159.1998.70052179.x","article-title":"Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices","volume":"70","author":"Kar","year":"1998","journal-title":"J. Neurochem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/brain\/awv318","article-title":"Amyloid-\u03b2 peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA\u03b2ACs","volume":"139","author":"Kumar","year":"2016","journal-title":"Brain"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3233\/JAD-142268","article-title":"Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value","volume":"44","author":"Lane","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.jalz.2010.12.005","article-title":"Butyrylcholinesterase genotype and gender influence Alzheimer\u2019s disease phenotype","volume":"9","author":"Lane","year":"2013","journal-title":"Alzheimers Dement."},{"key":"B34","volume-title":"Neuropsychological Assessment.","author":"Lezak","year":"2012"},{"key":"B35","doi-asserted-by":"publisher","first-page":"103885","DOI":"10.1016\/j.archger.2019.05.010","article-title":"A review of published anticholinergic scales and measures and their applicability in database analyses","volume":"87","author":"Lozano-Ortega","year":"2020","journal-title":"Arch. Gerontol. Geriatr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jcmm.12343","article-title":"Fibrillar \u03b2-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation","volume":"18","author":"Malmsten","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","article-title":"Cerebrospinal fluid tau, neurogranin and neurofilament light in Alzheimer\u2019s disease","volume":"8","author":"Mattsson","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"Mckeith","year":"2017","journal-title":"Neurology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Mckhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1467-9868.2010.00740.x","article-title":"Stability selection","volume":"72","author":"Meinshausen","year":"2010","journal-title":"J. R. Stat. Soc. Series B"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/cne.23415","article-title":"Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer\u2019s disease","volume":"521","author":"Mesulam","year":"2013","journal-title":"J. Comp. Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.410220206","article-title":"Cholinesterases within neurofibrillary tangles related to age and Alzheimer\u2019s disease","volume":"22","author":"Mesulam","year":"1987","journal-title":"Ann. Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/nbdi.2001.0462","article-title":"Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain","volume":"9","author":"Mesulam","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/ana.20100","article-title":"Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum","volume":"55","author":"Mesulam","year":"2004","journal-title":"Ann. Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1586\/14737175.8.11.1703","article-title":"Cholinergic system during the progression of Alzheimer\u2019s disease: therapeutic implications","volume":"8","author":"Mufson","year":"2008","journal-title":"Exp. Rev. Neurother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s0891-0618(03)00068-1","article-title":"Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction","volume":"26","author":"Mufson","year":"2003","journal-title":"J. Chem. Neuroanat."},{"key":"B48","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.neuropharm.2005.10.013","article-title":"Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors","volume":"50","author":"Nizri","year":"2006","journal-title":"Neuropharmacology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Curr. Alzheimer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"19377","DOI":"10.1074\/jbc.M111.321448","article-title":"Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-\u03b2 peptide oligomers","volume":"287","author":"Nunes-Tavares","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease and movement disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2008.06.011","article-title":"Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway","volume":"23","author":"Pavlov","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"8068","DOI":"10.1073\/pnas.93.15.8068","article-title":"Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain","volume":"93","author":"Pedersen","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/ageing\/9.1.9","article-title":"Histochemical observations on cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients","volume":"9","author":"Perry","year":"1980","journal-title":"Age Ageing"},{"key":"B55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3233\/JAD-160273","article-title":"Contribution of the cholinergic system to verbal memory performance in mild cognitive impairment","volume":"53","author":"Peter","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"B57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","article-title":"YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies","volume":"14","author":"Querol-Vilaseca","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"B58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12974-016-0725-1","article-title":"Immunomodulatory effects of nicotine on interleukin 1\u03b2 activated human astrocytes and the role of cyclooxygenase 2 in the underlying mechanism","volume":"13","author":"Revathikumar","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"B59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"Salahudeen","year":"2015","journal-title":"BMC Geriatr."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00702-006-0579-2","article-title":"The significance of the cholinergic system in the brain during aging and in Alzheimer\u2019s disease","volume":"113","author":"Schliebs","year":"2006","journal-title":"J. Neural Transm. (Vienna)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","article-title":"The cholinergic system in aging and neuronal degeneration","volume":"221","author":"Schliebs","year":"2011","journal-title":"Behav. Brain Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"624.e623","DOI":"10.1016\/j.neurobiolaging.2011.03.006","article-title":"Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice","volume":"33","author":"Silveyra","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"B63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-200964","article-title":"Cerebrospinal fluid C18 ceramide associates with markers of Alzheimer\u2019s disease and inflammation at the pre- and early stages of dementia","volume":"81","author":"Teitsdottir","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-020-00657-8","article-title":"Association of glial and neuronal degeneration markers with Alzheimer\u2019s disease cerebrospinal fluid profile and cognitive functions","volume":"12","author":"Teitsdottir","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J. R. Stat. Soc. Series B"},{"key":"B66","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/BF00307630","article-title":"Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex","volume":"80","author":"Ulrich","year":"1990","journal-title":"Acta Neuropathol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1086\/430323","article-title":"The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis","volume":"191","author":"Van Westerloo","year":"2005","journal-title":"J. Infect. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e65936","DOI":"10.1371\/journal.pone.0065936","article-title":"Regulated extracellular choline acetyltransferase activity- the plausible missing link of the distant action of acetylcholine in the cholinergic anti-inflammatory pathway","volume":"8","author":"Vijayaraghavan","year":"2013","journal-title":"PLoS One"},{"key":"B69","volume-title":"WMS-R : Wechsler Memory Scale\u2013Revised: Manual.","author":"Wechsler","year":"1987"},{"key":"B70","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","article-title":"Mild cognitive impairment\u2013beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment","volume":"256","author":"Winblad","year":"2004","journal-title":"J. Intern. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ana.410340312","article-title":"Neurological cholinesterases in the normal brain and in Alzheimer\u2019s disease: relationship to plaques, tangles and patterns of selective vulnerability","volume":"34","author":"Wright","year":"1993","journal-title":"Ann. Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.876019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T07:46:11Z","timestamp":1653551171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.876019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":73,"alternative-id":["10.3389\/fnagi.2022.876019"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.876019","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"876019"}}